New drug candidate blocks resistance to cancer therapies
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance. The design and preclinical evaluation of the inhibitor, MTX-531 was published in Nature Cancer. Researchers, led by Judith Sebolt-Leopold, Ph.D., discovered MTX-531, a kinase inhibitor with … Read more
